



CNA Diagnostics Inc.

- Proprietary platform technology and significant in-house expertise.
- Unique approach to molecular diagnostics and bioinformatics. All experiments to date have produced accurate results and identified diseases very early.
- Addressing highest economic diseases impacting people, pets and production animals.
- Standardized, repeatable, scalable processes.
- Out-license agreement in place to distribute upcoming bovine tests with major industry participant across 67 countries.
- Strategic Partnership with Ethos Veterinary Health to develop suite of diagnostic tests for the Companion Animal Market.
- Aggressively expanding human sepsis diagnostic.
- Stay within niche and employ channel partners.
- Low SG&A as we scale up. Investment dollars for R&D.

CNA Diagnostics Inc. (CNAD) is a Molecular Diagnostics company developing disruptive diagnostic tests for a wide spectrum of complex diseases affecting people, pets and production animals.

Our technology and expertise allows for disease detection long before the occurrence of clinical signs which allows for early therapeutic treatment.

We can accurately diagnose diseases where there are limited accurate tests.



Circulating Nucleic Acids (CNA)

The body responds to challenges as it fights to return to normal. At the same time, cells die as part of normal life and DNA information regarding cell activity is released into the blood.

Unique chromosomal regions only in specific disease states are identified.

Diagnostic tests are designed that alert practitioners when a disease state is forming - before clinical signs and with high accuracy. Standard hardware can be used. No large infrastructure investment required.



Strategy

- Offering contract research services for select enterprise customers in production animals to produce short term profit
- Deploy retained earnings to high margin companion animal diagnostic tests
- Aggressively completing experiments on human sepsis. Massive upside potential with limited invested capital required
- Out-licensing upcoming tests with multiple partners to spread performance risk
- Maintaining and building strategic partnerships to maximize access to samples
- Field tests for Johnes and Bovine Respiratory Disease planned beginning Q2 2018, followed by full product roll out
- Bacterial and Fungal human sepsis proof of concept Phase 2 in late 2018

Human Bacterial Sepsis
- Up to 3 days before symptoms

Bovine Spongiform Encephalopathy
- 10 months before symptoms

Chronic Wasting Disease - 10 months before symptoms

Non Lethal Radiation - 1 hour after exposure

Paratuberculosis - Results Q2 2018

Bovine Respiratory Disease - Results Q3 2018

Human Sepsis Phase 2 - Results Q4 2018



Management

David L. Gordon, Bcomm, PMP, CFA CEO

David is a business and financial professional with +15 years experience optimizing business performance and effectively deploying capital to maximize an organization's potential. David has comanaged a \$3.0 billion North American equity fund; conducted the turnaround of a municipal water utility including direct oversight and responsibility of \$1.4 billion capex over 4 years, \$330 million annual opex, and a team of 20 FTEs. David has managed an \$85 million land development portfolio, raised over \$125 million (in collaboration with partners) for SMEs and small pubcos, and conducted complex private equity transactions for middle market companies in the range of \$10-\$60 million while investment banking with CIBC.

He has been appointed CFO to multiple SMEs within the technology landscape from crypto-currency to enterprise middleware. He holds a Chartered Financial Analyst (CFA) designation and is a Project Management Professional (PMP) and well as the Top Graduate within his Bcomm program.

David is a published author on strategy execution. David is experienced in the unique challenges facing small and quickly growing entities, he is full of grit and determination, and loves bringing disruptive technologies to market.

Dr. Christoph W. Sensen CSO

The founding member of CNA Diagnostics Inc., Dr. Sensen is a University Professor for Computational Biotechnology at the Graz University of Technology in Austria and an Adjunct Professor at the University of Calgary's Faculty of Medicine, Department of Biochemistry and Molecular Biology. He participated in several large-scale Genome Research programs, including two for the development of markers for CWD and BSE, and co-Author on more than 100 peer-reviewed articles and has edited or published six books in the field of Genome Research and Bioinformatics. Dr. Sensen is a reviewer for granting agencies and Journals; and Chief Editor at Journal of Biotechnology (Elsevier).

Previously he worked for seven years as a Research Officer at the National Research Council of Canada's Institute for Marine Biosciences (NRC-IMB) and as a visiting scientist at the European Molecular Biology Laboratory (EMBL) in Heidelberg (13 months). He studied Biology in Mainz, Düsseldorf and Cologne and obtained a Dr. rer. nat. degree from the University of Cologne in 1994.

Share Structure & Valuation

16.5M Common Shares • 1.4M Options • 1.3M Warrants
\$9.6M CAD Pre-Money

Independent Board

Dr. Greg Andrews
Chairman, Director

Todd Wallach Director

Alec Milne Director

Dr. G. Kee Jim Director

Dennis L. Nerland, QC Director

Advisory Board

Dr. Robert B. Church

Dr. David Chalack

Dr. Renaud Leguilette



CNA Diagnostics Inc.